BioCentury | Aug 15, 2020
Management Tracks

Myriad chooses Diaz as new CEO; plus changes at Novocure, Werewolf, Jasper, Avacta, Tarsus and more

Former Kindred Healthcare CEO Paul Diaz has become president and CEO of Myriad Genetics Inc. (NASDAQ:MYGN). He replaces Mark Capone, who left the molecular diagnostics company in February after the company’s fiscal 2Q earnings disappointed. Mike...
BioCentury | Feb 8, 2020
Product Development

Feb. 7 Product Development Quick Takes: Myriad tumbles on revenue miss; plus Verana, Sanofi, VIB, Coda, Blueprint

Myriad misses Street as CEO Capone departs Myriad Genetics Inc. (NASDAQ:MYGN) fell $8.27 (28%) to $21.02 after reporting fiscal 2Q20 EPS and revenues that missed consensus estimates and announcing the departure of President and CEO...
BioCentury | Dec 31, 2018
Company News

Management tracks: Myriad co-founder Meldrum passes away

Peter Meldrum, co-founder and former CEO of Myriad Genetics Inc. (NASDAQ:MYGN), passed away on Dec. 20 at the age of 71. Meldrum retired from the molecular diagnostics company in 2015, when Mark Capone became president...
BioCentury | Sep 7, 2015
Strategy

Back to School 2015: Changing the subject

No longer content with a walk-on role as research subjects, and empowered by access to more information and the necessity of shouldering a bigger share of the healthcare bill, patients are demanding a speaking role...
BioCentury | Jun 8, 2015
Product Development

Out with the old

Data presented at the American Society of Clinical Oncology meeting in Chicago in previously treated multiple myeloma offer the tantalizing prospect that new regimens could move up to supplant Velcade bortezomib as standard of care...
BioCentury | Jun 4, 2015
Strategy

Cause, Not Correlation

The Multiple Myeloma Research Foundation (MMRF) is tapping into the computing power of GNS Healthcare Inc. to analyze patients' clinical, genome and transcriptome data with the goal of finding hidden variables that don't just correlate...
BioCentury | May 30, 2015
Clinical News

Farydak/Kyprolis ORR tops Velcade combo in MM

Data due to be presented Tuesday at the American Society of Clinical Oncology meeting in Chicago showed a combination of Farydak panobinostat from Novartis AG (NYSE:NVS; SIX:NOVN) and Kyprolis carfilzomib from Amgen Inc. (NASDAQ:AMGN) led...
BioCentury | May 21, 2015
Targets & Mechanisms

Intersection in marrow

An unlikely connection between Gaucher's disease and multiple myeloma has been uncovered by a U.K. group that found a common node in the pathways responsible for the bone disease symptoms that accompany both diseases. Suppression...
BioCentury | Nov 17, 2014
Regulation

Panobinostat push back

FDA's Oncologic Drugs Advisory Committee was unmoved by Novartis AG 's argument that elevated rates of serious adverse events and on-treatment deaths seen in a global Phase III trial of panobinostat were the result of...
BioCentury | Sep 29, 2014
Company News

Medidata Solutions management update

Medidata Solutions Inc. (NASDAQ:MDSO), New York, N.Y. Business: Bioinformatics Hired: Michael Capone as COO, a newly created position, formerly corporate VP of product development and chief information officer of ADP LLC WIR Staff...
Items per page:
1 - 10 of 13